Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine — REPLAY

Invasive Pneumococcal Disease Clinical Trial

Official title:
REVACCINATION WITH PREVENAR 13 - CHARACTERIZATION OF THE LATE IMMUNE RESPONSE AFTER POLYSACCHARIDE (REPLAY).

Status Completed

Clinical Trial Summary

The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and pneumococcal polysaccharide vaccine (PSV). This study is also intended to evaluate the safety of the 13vPnC.

Clinical Trial Description

Follow-up measure for the EMEA supporting a Type II variation for Prevenar (PCV7) label ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00853749
Study type	Interventional
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	May 5, 2009
Completion date	December 16, 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00227188` - Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.	N/A
Recruiting	`NCT00885625` - 7-valent Pneumococcal Conjugated Vaccination	Phase 4
Completed	`NCT04464291` - An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years	N/A
Completed	`NCT01128439` - Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
Completed	`NCT01083459` - Impact of PCV on Disease and Colonization Among Native American Communities	N/A
Completed	`NCT00371878` - Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection	Phase 4